$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000162828021014464 Filed on July 26, 2021

Income Statement

Concept	2021 Q1	2020 Q2	2020
Revenue	$10.81M	$8.750M	$32.12M
YoY Change	19.97%	13.34%	1007.69%
Cost Of Revenue	$4.623M	$4.920M	$17.00M
YoY Change	6.89%	14.42%	19.13%
Gross Profit	$6.189M	$3.820M	$15.12M
YoY Change	32.05%	11.7%	18.15%
Gross Profit Margin	57.24%	43.66%	47.08%
Selling, General & Admin	$3.328M	$3.580M	$10.86M
YoY Change	16.24%	56.33%	40.37%
% of Gross Profit	53.77%	93.72%	71.78%
Research & Development	$1.879M	$1.820M	$5.853M
YoY Change	35.08%	45.6%	21.99%
% of Gross Profit	30.36%	47.64%	38.7%
Depreciation & Amortization	$279.0K	$250.0K	$825.0K
YoY Change	51.63%	38.89%	36.14%
% of Gross Profit	4.51%	6.54%	5.46%
Operating Expenses	$5.207M	$5.400M	$33.93M
YoY Change	-39.31%	52.54%	26.6%
Operating Profit	$982.0K	-$1.580M	-$1.921M
YoY Change	126.79%	1216.67%	-811.48%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$8.000K	-$40.00K	-$42.00K
YoY Change	-42.86%	33.33%	7.69%
Pretax Income	$974.0K	-$1.960M	-$1.963M
YoY Change	132.46%	1206.67%	-949.78%
Income Tax	$15.00K	$90.00K	$130.0K
% Of Pretax Income	1.54%
Net Earnings	$959.0K	-$2.050M	-$2.093M
YoY Change	1178.67%	720.0%	-1735.16%
Net Earnings / Revenue	8.87%	-23.43%	-6.52%
Basic Earnings Per Share	$0.07		-$0.18
Diluted Earnings Per Share	$0.07	-$165.2K	-$0.18
COMMON SHARES
Basic Shares Outstanding	13.37M shares		11.84M shares
Diluted Shares Outstanding	14.51M shares		11.84M shares

Balance Sheet

Concept	2021 Q1	2020 Q2	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.430M	$8.340M	$8.340M
YoY Change	126.52%	157.41%	157.41%
Cash & Equivalents	$7.400M	$8.342M	$8.340M
Short-Term Investments
Other Short-Term Assets	$420.0K	$390.0K	$390.0K
YoY Change	16.67%	25.81%	25.81%
Inventory
Prepaid Expenses
Receivables	$6.121M	$4.770M	$4.770M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.97M	$13.50M	$13.50M
YoY Change	71.82%	70.37%	70.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.540M	$3.993M	$6.790M
YoY Change	70.67%	56.83%	166.27%
Goodwill	$335.0K	$335.0K
YoY Change	-49.93%	-49.93%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$128.0K	$130.0K
YoY Change	-71.88%	0.0%	0.0%
Total Long-Term Assets	$11.29M	$7.254M	$7.250M
YoY Change	62.58%	116.99%	116.42%
TOTAL ASSETS
Total Short-Term Assets	$13.97M	$13.50M	$13.50M
Total Long-Term Assets	$11.29M	$7.254M	$7.250M
Total Assets	$25.26M	$20.75M	$20.75M
YoY Change	67.56%	84.21%	84.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.745M	$3.140M	$3.140M
YoY Change	-21.22%	11.86%	11.74%
Accrued Expenses	$2.207M	$2.721M	$3.010M
YoY Change	125.66%	130.59%	155.08%
Deferred Revenue	$6.615M	$5.800M
YoY Change	44.24%	44.21%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$130.0K	$130.0K
YoY Change	-100.0%	550.0%	550.0%
Total Short-Term Liabilities	$11.20M	$12.30M	$12.09M
YoY Change	32.55%	53.32%	50.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$181.0K	$178.0K	$3.350M
YoY Change	19.87%	17.88%	235.0%
Total Long-Term Liabilities	$181.0K	$178.0K	$3.350M
YoY Change	19.87%	17.88%	235.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.20M	$12.30M	$12.09M
Total Long-Term Liabilities	$181.0K	$178.0K	$3.350M
Total Liabilities	$17.17M	$15.65M	$15.43M
YoY Change	44.34%	73.39%	70.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.64M	-$72.89M
YoY Change	1.47%	3.1%
Common Stock	$79.72M	$77.99M
YoY Change	8.02%	6.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.086M	$5.099M	$5.320M
YoY Change
Total Liabilities & Shareholders Equity	$25.26M	$20.75M	$20.75M
YoY Change	67.56%	84.21%	84.12%

Cashflow Statement

Concept	2021 Q1	2020 Q2	2020
OPERATING ACTIVITIES
Net Income	$959.0K	-$2.050M	-$2.093M
YoY Change	1178.67%	720.0%	-1735.16%
Depreciation, Depletion And Amortization	$279.0K	$250.0K	$825.0K
YoY Change	51.63%	38.89%	36.14%
Cash From Operating Activities	$140.0K	$2.550M	$2.905M
YoY Change	-50.0%	920.0%	56.02%
INVESTING ACTIVITIES
Capital Expenditures	-$1.210M	-$1.530M	$2.220M
YoY Change	611.76%	992.86%	166.19%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$1.210M	-$1.530M	-$2.220M
YoY Change	611.76%	992.86%	166.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-60.00K	4.040M	$4.420M
YoY Change	-115.38%	-2226.32%	267.41%
NET CHANGE
Cash From Operating Activities	140.0K	2.550M	$2.905M
Cash From Investing Activities	-1.210M	-1.530M	-$2.220M
Cash From Financing Activities	-60.00K	4.040M	$4.420M
Net Change In Cash	-1.130M	5.060M	$5.105M
YoY Change	-326.0%	-6425.0%	128.82%
FREE CASH FLOW
Cash From Operating Activities	$140.0K	$2.550M	$2.905M
Capital Expenditures	-$1.210M	-$1.530M	$2.220M
Free Cash Flow	$1.350M	$4.080M	$685.0K
YoY Change	200.0%	946.15%	-33.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ServiceMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ServiceMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ServiceMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ServiceMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-04-30
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-11504
CY2021	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1401755
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	One University Plaza, Suite 307
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07601
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Hackensack
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2021	dei	City Area Code CityAreaCode	201
CY2020Q2	us-gaap	Assets Assets	20751000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1894000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3140000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2231000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2721000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	818000	USD
CY2021	dei	Local Phone Number LocalPhoneNumber	808-8400
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	CSBR
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Public Float EntityPublicFloat	50100000	USD
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13415066	shares
CY2021Q2	us-gaap	Cash Cash	4687000	USD
CY2020Q2	us-gaap	Cash Cash	8342000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6986000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4770000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	957000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	385000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	12630000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	13497000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8521000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2798000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6090000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3993000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2021Q2	us-gaap	Assets Assets	27591000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5815000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	125000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6256000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11199000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12304000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8783000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3170000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	181000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	20163000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	15652000	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13414066	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13414066	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12726728	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12726728	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	79945000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	77978000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72530000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72892000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7428000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5099000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27591000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20751000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41040000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32123000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21446000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17000000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7196000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5853000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5520000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4242000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6512000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6614000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	335000	USD
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	40674000	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	34044000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	366000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1921000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	437000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1963000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	362000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	7428000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2093000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13138995	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11843463	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14573561	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11843463	shares
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	2137000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	600000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4455000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2093000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5099000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	598000	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1369000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	362000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	362000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2093000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	598000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	600000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1184000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	825000	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	52000	USD
CY2021	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	398000	USD
CY2020	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	403000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	335000	USD
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	75000	USD
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	49000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	277000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2265000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	670000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	572000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	77000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1246000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	333000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-316000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1440000	USD
CY2021	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	242000	USD
CY2020	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	235000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	27000	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	441000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1792000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1681000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2905000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3281000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2220000	USD
CY2021	csbr	Proceeds From Refund Of Security Deposit ProceedsFromRefundOfSecurityDeposit	112000	USD
CY2020	csbr	Proceeds From Refund Of Security Deposit ProceedsFromRefundOfSecurityDeposit	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3169000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2220000	USD
CY2021	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	1369000	USD
CY2020	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	4455000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	174000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	35000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1195000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4420000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3655000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5105000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8342000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3237000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4687000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8342000	USD
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	212000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6121000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3201000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	160000	USD
CY2021	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounts receivable realization, revenue recognition, valuation allowance for deferred tax assets, valuation of goodwill, recoverability of capitalized software development costs, and stock-based compensation and warrant assumptions. We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources. Actual amounts could differ significantly from amounts previously estimated.</span></div>
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2721000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12304000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	15652000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72892000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5099000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17000000	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	34044000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1921000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2093000	USD
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4623000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15603000	USD
CY2021Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9830000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	29462000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	982000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1014000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	959000	USD
	us-gaap	Net Income Loss NetIncomeLoss	1035000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2207000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2207000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11195000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11195000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	17174000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	17174000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71638000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71638000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8086000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8086000	USD
CY2021Q2	us-gaap	Cash Cash	4700000	USD
CY2020Q2	us-gaap	Cash Cash	8300000	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	362000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72500000	USD
CY2021Q2	csbr	Working Capital WorkingCapital	1400000	USD
CY2021Q2	us-gaap	Cash Cash	4700000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	335000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	3000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	27000000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2021Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	4304000	USD
CY2020Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	2655000	USD
CY2021Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3020000	USD
CY2020Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2404000	USD
CY2021Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	7324000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5059000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	338000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	289000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6986000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4770000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6256000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5815000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10046000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6765000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3956000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2772000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6090000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3993000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1200000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	825000	USD
CY2021	csbr	Finance Lease Depreciationand Amortization Expenses FinanceLeaseDepreciationandAmortizationExpenses	925000	USD
CY2020	csbr	Finance Lease Depreciationand Amortization Expenses FinanceLeaseDepreciationandAmortizationExpenses	683000	USD
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	343000	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	343000	USD
CY2021	us-gaap	Hosting Arrangement Service Contract Implementation Cost Expense Amortization HostingArrangementServiceContractImplementationCostExpenseAmortization	134000	USD
CY2021Q2	us-gaap	Hosting Arrangement Service Contract Implementation Cost Capitalized Accumulated Amortization HostingArrangementServiceContractImplementationCostCapitalizedAccumulatedAmortization	991000	USD
	csbr	Finance Lease Cost FinanceLeaseCost	149000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000	USD
CY2018Q3	csbr	Finance Lease Cost FinanceLeaseCost	266000	USD
CY2018Q3	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	11000	USD
CY2019Q4	csbr	Number Of Assets Acquired NumberOfAssetsAcquired	2	asset
CY2019Q4	csbr	Finance Lease Cost FinanceLeaseCost	231000	USD
CY2019Q4	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	19000	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	0	USD
CY2020Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	135000	USD
CY2019Q4	csbr	Present Value Minimum Future Obligations Interest Rate PresentValueMinimumFutureObligationsInterestRate	0.0475
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	124000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88500	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41040000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32123000	USD
CY2021	us-gaap	Royalty Expense RoyaltyExpense	127000	USD
CY2020	us-gaap	Royalty Expense RoyaltyExpense	128000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	598000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	598000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2013Q4	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	16667	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.001
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.005
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.013
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.70
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.75
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.11
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.33
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2271658	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.23
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10663000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	135834	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.24
CY2021	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y3M18D
CY2021	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	259000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	687338	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.33
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.04
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2271658	shares
CY2021	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	48674	shares
CY2021	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	6.03
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.48
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	5834	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.80
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1653646	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.96
CY2021	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y4M24D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11384000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1653646	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.96
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11384000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1332854	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.34
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M18D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9995000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2423626	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.19
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14557000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	229833	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.33
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y1M6D
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	544000	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	248495	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.31
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	11824	shares
CY2020	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	7.96
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	44813	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.85
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	76669	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.23
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10663000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2271658	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.23
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10663000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1943618	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.83
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9898000	USD
CY2021Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	0	shares
CY2020Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	0	shares
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3900000	USD
CY2021	csbr	Stock Issued During Period Shares Stock Options And Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised	161000	shares
CY2020	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised	10045000	USD
CY2020	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited	8587000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	62000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	75000	USD
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	13000	USD
CY2021	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	62000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	75000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	127000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	130000	USD
CY2020	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	3000	USD
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	127000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.808
CY2020Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	175000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.169
CY2021	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.615
CY2020	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.140
CY2021	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	-0.007
CY2020	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.035
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.243
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.172
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.066
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	232000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	77000	USD
CY2021Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	206000	USD
CY2021Q2	csbr	Deferred Tax Assets Tax Deferred Expense Right Of Use Asset Liability DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability	271000	USD
CY2020Q2	csbr	Deferred Tax Assets Tax Deferred Expense Right Of Use Asset Liability DeferredTaxAssetsTaxDeferredExpenseRightOfUseAssetLiability	226000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11404000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11223000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3640000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4109000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15341000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15460000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15341000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15460000	USD
CY2021Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q2	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	15300000	USD
CY2020Q2	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	15300000	USD
CY2021Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	46900000	USD
CY2020Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	45000000.0	USD
CY2013Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	12000000.0	USD
CY2021Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	432000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	27000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	181000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	362000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2093000	USD
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13138995	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11843463	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	362000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2093000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	362000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2093000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13138995	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11843463	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1434566	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14573561	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11843463	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1653646	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2271658	shares
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1247000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	955000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P6M
CY2021	csbr	Operating Lease Incremental Rent Expense OperatingLeaseIncrementalRentExpense	43000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3300000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8521000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2798000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	818000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8783000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3170000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M10D
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2437000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2530000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2673000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2713000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2757000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7904000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	21014000	USD

Files In Submission

Name	View Source	Status
0001628280-21-014464-index-headers.html	Edgar Link	pending
0001628280-21-014464-index.html	Edgar Link	pending
0001628280-21-014464.txt	Edgar Link	pending
0001628280-21-014464-xbrl.zip	Edgar Link	pending
csbr-20210430.htm	Edgar Link	pending
csbr-20210430.xsd	Edgar Link	pending
csbr-20210430_cal.xml	Edgar Link	unprocessable
csbr-20210430_def.xml	Edgar Link	unprocessable
csbr-20210430_htm.xml	Edgar Link	completed
csbr-20210430_lab.xml	Edgar Link	unprocessable
csbr-20210430_pre.xml	Edgar Link	unprocessable
csbrex2314302021.htm	Edgar Link	pending
csbrex3114302021.htm	Edgar Link	pending
csbrex3124302021.htm	Edgar Link	pending
csbrex3214302021.htm	Edgar Link	pending
csbrex414302021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2021 Q1 Form 10-K Financial Statement

#000162828021014464 Filed on July 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2021 Q1 Form 10-K Financial Statement

#000162828021014464 Filed on July 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr